Literature DB >> 9474053

Therapeutic drug monitoring in special populations.

P D Walson1.   

Abstract

Therapeutic drug monitoring (TDM) is commonly used to maintain "therapeutic" drug concentrations. Even in compliant patients, with "average" drug kinetics, TDM is useful to identify the causes of unwanted or unexpected responses, prevent unnecessary diagnostic testing, improve clinical outcomes, and even save lives. TDM has greatest promise in certain special populations who are: (a) prone to under- or overrespond to usual dosing regimens, (b) least able to tolerate, recognize, or communicate drug effects, or who are (c) intentionally or accidentally misdosed. TDM is especially useful in patients at the extremes of age, in adolescents, and in patients who are either taking multiple drugs or expressing unusual pharmacokinetics as a result of physiological, environmental, or genetic causes. Less-well-appreciated uses of TDM include prevention of dangerous underdosing of patients, investigation of adverse drug reactions, and identification of serious medication errors, even for a number of drugs that are not traditionally monitored. TDM can be useful for some drugs in any patient and for most drugs in some special populations.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9474053

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  7 in total

Review 1.  Therapeutic drug monitoring: do the improved outcomes justify the costs?

Authors:  G E Schumacher; J T Barr
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Are higher vancomycin doses needed in ventricle-external shunted patients?

Authors:  Meritxell Pujal; Dolors Soy; Carles Codina; Josep Ribas
Journal:  Pharm World Sci       Date:  2006-10-26

Review 3.  Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions.

Authors:  M Gex-Fabry; A E Balant-Gorgia; L P Balant
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  Transdermal reverse iontophoresis of valproate: a noninvasive method for therapeutic drug monitoring.

Authors:  M Begoña Delgado-Charro; Richard H Guy
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

Review 5.  Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Authors:  F Pea; M Furlanut
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

6.  Drug therapy and adverse drug reactions to terbutaline in obstetric patients: a prospective cohort study in hospitalized women.

Authors:  Dulce Hernández-Hernández; María Vargas-Rivera; Alejandro A Nava-Ocampo; José Palma-Aguirre; Héctor Sumano-López
Journal:  BMC Pregnancy Childbirth       Date:  2002-04-05       Impact factor: 3.007

Review 7.  On the Slow Diffusion of Point-of-Care Systems in Therapeutic Drug Monitoring.

Authors:  Barbara Sanavio; Silke Krol
Journal:  Front Bioeng Biotechnol       Date:  2015-02-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.